-

Shattuck Labs to Present at 40th Annual Cowen Health Care Conference

AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and other diseases, today announced that Shattuck Labs’ Chief Executive Officer, Taylor Schreiber, M.D., Ph.D., will present at the 40th Annual Cowen Health Care Conference on Wednesday, March 4 at 9:30 a.m. ET in Boston.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and other diseases. The Company’s lead investigational new medicine SL-279252 (PD1-Fc-OX40L), a proprietary bi-functional fusion protein, has the potential to be a best-in-class therapy for solid tumors and lymphomas. Using its ARC™ platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: http://www.shattucklabs.com.

Contacts

Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
investors@shattucklabs.com

Media Contact:
Daniella Funaro
Stern Investor Relations, Inc.
212-362-1200
Daniella.Funaro@sternir.com

Industry:

Shattuck Labs, Inc.

Release Versions
English

Contacts

Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
investors@shattucklabs.com

Media Contact:
Daniella Funaro
Stern Investor Relations, Inc.
212-362-1200
Daniella.Funaro@sternir.com

More News From Shattuck Labs, Inc.

Shattuck Labs to Present at TIGIT Therapies Digital Summit 2020

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the TIGIT Therapies Digital Summit 2020 being held virtually October 26 – 27, 2020. Presentation Details Presentation Title: Using LIGHT to Hotwire TIGIT Blockade Date/Time: October...

Shattuck Labs Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the closing of its upsized initial public offering of 13,664,704 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,782,352 additional shares of commo...

Shattuck Labs Announces Pricing of Upsized Initial Public Offering

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the pricing of its upsized initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Shattuck from the offering, before deducting underwriting...
Back to Newsroom